Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Cristofanilli

Showing results (331-340 of 442) with videos related to

Pageof 45
Sort By:
Critical Reviews in Oncology/Hematology|May 20, 2020
Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)Christian Rolfo, Andrés F Cardona, Massimo Cristofanilli, et al.
Critical Reviews in Oncology/Hematology|August 22, 2020
Corrigendum to "Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)" [Crit. Rev. Oncol. Hematol. 151 (July) (2020) 102978]Christian Rolfo, Andrés F Cardona, Massimo Cristofanilli, et al.
Breast Cancer Research : BCR|January 10, 2015
Circulating tumor cells in newly diagnosed inflammatory breast cancerMichal Mego, Antonio Giordano, Ugo De Giorgi, et al.
Breast Cancer Research : BCR|June 25, 2011
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatmentMario Giuliano, Antonio Giordano, Summer Jackson, et al.
The Oncologist|December 8, 2011
Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancerJing Li, Ana M Gonzalez-Angulo, Pamela K Allen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancerUgo De Giorgi, Vicente Valero, Eric Rohren, et al.
International Journal of Radiation Oncology, Biology, Physics|April 29, 2008
Locoregional treatment outcomes after multimodality management of inflammatory breast cancerIan J Bristol, Wendy A Woodward, Eric A Strom, et al.
Cancer Cell International|December 24, 2025
Quantitative HER2 profiling on circulating tumor cells using an EpCAM-independent platform in metastatic breast cancerNadia Bayou, Sarah Henretta, Laura Munoz-Arcos, et al.
CA: a Cancer Journal for Clinicians|October 21, 2010
Inflammatory breast cancer: the disease, the biology, the treatmentFredika M Robertson, Melissa Bondy, Wei Yang, et al.
Oncotarget|July 5, 2016
Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancerMichal Mego, Hui Gao, Evan N Cohen, et al.
Pageof 45

Showing results (331-340 of 442) with videos related to

Sort By:
Pageof 45
Critical Reviews in Oncology/Hematology|May 20, 2020
Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)Christian Rolfo, Andrés F Cardona, Massimo Cristofanilli, et al.
Critical Reviews in Oncology/Hematology|August 22, 2020
Corrigendum to "Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)" [Crit. Rev. Oncol. Hematol. 151 (July) (2020) 102978]Christian Rolfo, Andrés F Cardona, Massimo Cristofanilli, et al.
Breast Cancer Research : BCR|January 10, 2015
Circulating tumor cells in newly diagnosed inflammatory breast cancerMichal Mego, Antonio Giordano, Ugo De Giorgi, et al.
Breast Cancer Research : BCR|June 25, 2011
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatmentMario Giuliano, Antonio Giordano, Summer Jackson, et al.
The Oncologist|December 8, 2011
Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancerJing Li, Ana M Gonzalez-Angulo, Pamela K Allen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancerUgo De Giorgi, Vicente Valero, Eric Rohren, et al.
International Journal of Radiation Oncology, Biology, Physics|April 29, 2008
Locoregional treatment outcomes after multimodality management of inflammatory breast cancerIan J Bristol, Wendy A Woodward, Eric A Strom, et al.
Cancer Cell International|December 24, 2025
Quantitative HER2 profiling on circulating tumor cells using an EpCAM-independent platform in metastatic breast cancerNadia Bayou, Sarah Henretta, Laura Munoz-Arcos, et al.
CA: a Cancer Journal for Clinicians|October 21, 2010
Inflammatory breast cancer: the disease, the biology, the treatmentFredika M Robertson, Melissa Bondy, Wei Yang, et al.
Oncotarget|July 5, 2016
Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancerMichal Mego, Hui Gao, Evan N Cohen, et al.
Pageof 45